Immune regulatory effects of simvastatin on regulatory T cell-mediated tumour immune tolerance

Sung Yong Lee, K. J. Lee, J. Y. Moon, H. K. Choi, H. O. Kim, Gyu Young Hur, K. H. Jung, S. Y. Lee, J. H. Kim, Chol Shin, Jae Jeong Shim, Kwang Ho In, S. H. Yoo, Kyung Ho Kang

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Statins are potent inhibitors of hydroxyl-3-methylglutaryl co-enzyme A (HMG-CoA) reductase, and have emerged as potential anti-cancer agents based on preclinical evidence. In particular, compelling evidence suggests that statins have a wide range of immunomodulatory properties. However, little is known about the role of statins in tumour immune tolerance. Tumour immune tolerance involves the production of immunosuppressive molecules, such as interleukin (IL)-10, transforming growth factor (TGF)- and indoleamine-2,3-dioxygenase (IDO) by tumours, which induce a regulatory T cell (Treg) response. In this study, we investigated the effect of simvastatin on the production of IL-10, TGF- and IDO production and the proliferation of Tregs using several cancer cell lines, and Lewis lung cancer (3LL) cells-inoculated mouse tumour model. Simvastatin treatment resulted in a decrease in the number of cancer cells (3LL, A549 and NCI-H292). The production of the immune regulatory markers IL-10, TGF- in 3LL and NCI-H292 cells increased after treatment with simvastatin. The expression of IDO and forkhead box P3 (FoxP3) transcription factor was also increased in the presence of simvastatin. In a murine 3LL model, there were no significant differences in tumour growth rate between untreated and simvastatin-treated mice groups. Therefore, while simvastatin had an anti-proliferative effect, it also exhibited immune tolerance-promoting properties during tumour development. Thus, due to these opposing actions, simvastatin had no net effect on tumour growth.

Original languageEnglish
Pages (from-to)298-305
Number of pages8
JournalClinical and Experimental Immunology
Volume161
Issue number2
DOIs
Publication statusPublished - 2010 Aug 1

Fingerprint

Immune Tolerance
Simvastatin
Regulatory T-Lymphocytes
Neoplasms
Indoleamine-Pyrrole 2,3,-Dioxygenase
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Transforming Growth Factors
Interleukin-10
Forkhead Transcription Factors
Immunosuppressive Agents
Growth
Hydroxyl Radical
Lung Neoplasms
Oxidoreductases
Cell Count
Biomarkers
Cell Line

Keywords

  • indoleamine-2,3-dioxygenase
  • interleukin-10
  • regulatory T cell
  • statin
  • transforming growth factor-β

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Immune regulatory effects of simvastatin on regulatory T cell-mediated tumour immune tolerance. / Lee, Sung Yong; Lee, K. J.; Moon, J. Y.; Choi, H. K.; Kim, H. O.; Hur, Gyu Young; Jung, K. H.; Lee, S. Y.; Kim, J. H.; Shin, Chol; Shim, Jae Jeong; In, Kwang Ho; Yoo, S. H.; Kang, Kyung Ho.

In: Clinical and Experimental Immunology, Vol. 161, No. 2, 01.08.2010, p. 298-305.

Research output: Contribution to journalArticle

Lee, Sung Yong ; Lee, K. J. ; Moon, J. Y. ; Choi, H. K. ; Kim, H. O. ; Hur, Gyu Young ; Jung, K. H. ; Lee, S. Y. ; Kim, J. H. ; Shin, Chol ; Shim, Jae Jeong ; In, Kwang Ho ; Yoo, S. H. ; Kang, Kyung Ho. / Immune regulatory effects of simvastatin on regulatory T cell-mediated tumour immune tolerance. In: Clinical and Experimental Immunology. 2010 ; Vol. 161, No. 2. pp. 298-305.
@article{f5af10be70a54fcabcc05751cb4187d0,
title = "Immune regulatory effects of simvastatin on regulatory T cell-mediated tumour immune tolerance",
abstract = "Statins are potent inhibitors of hydroxyl-3-methylglutaryl co-enzyme A (HMG-CoA) reductase, and have emerged as potential anti-cancer agents based on preclinical evidence. In particular, compelling evidence suggests that statins have a wide range of immunomodulatory properties. However, little is known about the role of statins in tumour immune tolerance. Tumour immune tolerance involves the production of immunosuppressive molecules, such as interleukin (IL)-10, transforming growth factor (TGF)- and indoleamine-2,3-dioxygenase (IDO) by tumours, which induce a regulatory T cell (Treg) response. In this study, we investigated the effect of simvastatin on the production of IL-10, TGF- and IDO production and the proliferation of Tregs using several cancer cell lines, and Lewis lung cancer (3LL) cells-inoculated mouse tumour model. Simvastatin treatment resulted in a decrease in the number of cancer cells (3LL, A549 and NCI-H292). The production of the immune regulatory markers IL-10, TGF- in 3LL and NCI-H292 cells increased after treatment with simvastatin. The expression of IDO and forkhead box P3 (FoxP3) transcription factor was also increased in the presence of simvastatin. In a murine 3LL model, there were no significant differences in tumour growth rate between untreated and simvastatin-treated mice groups. Therefore, while simvastatin had an anti-proliferative effect, it also exhibited immune tolerance-promoting properties during tumour development. Thus, due to these opposing actions, simvastatin had no net effect on tumour growth.",
keywords = "indoleamine-2,3-dioxygenase, interleukin-10, regulatory T cell, statin, transforming growth factor-β",
author = "Lee, {Sung Yong} and Lee, {K. J.} and Moon, {J. Y.} and Choi, {H. K.} and Kim, {H. O.} and Hur, {Gyu Young} and Jung, {K. H.} and Lee, {S. Y.} and Kim, {J. H.} and Chol Shin and Shim, {Jae Jeong} and In, {Kwang Ho} and Yoo, {S. H.} and Kang, {Kyung Ho}",
year = "2010",
month = "8",
day = "1",
doi = "10.1111/j.1365-2249.2010.04170.x",
language = "English",
volume = "161",
pages = "298--305",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Immune regulatory effects of simvastatin on regulatory T cell-mediated tumour immune tolerance

AU - Lee, Sung Yong

AU - Lee, K. J.

AU - Moon, J. Y.

AU - Choi, H. K.

AU - Kim, H. O.

AU - Hur, Gyu Young

AU - Jung, K. H.

AU - Lee, S. Y.

AU - Kim, J. H.

AU - Shin, Chol

AU - Shim, Jae Jeong

AU - In, Kwang Ho

AU - Yoo, S. H.

AU - Kang, Kyung Ho

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Statins are potent inhibitors of hydroxyl-3-methylglutaryl co-enzyme A (HMG-CoA) reductase, and have emerged as potential anti-cancer agents based on preclinical evidence. In particular, compelling evidence suggests that statins have a wide range of immunomodulatory properties. However, little is known about the role of statins in tumour immune tolerance. Tumour immune tolerance involves the production of immunosuppressive molecules, such as interleukin (IL)-10, transforming growth factor (TGF)- and indoleamine-2,3-dioxygenase (IDO) by tumours, which induce a regulatory T cell (Treg) response. In this study, we investigated the effect of simvastatin on the production of IL-10, TGF- and IDO production and the proliferation of Tregs using several cancer cell lines, and Lewis lung cancer (3LL) cells-inoculated mouse tumour model. Simvastatin treatment resulted in a decrease in the number of cancer cells (3LL, A549 and NCI-H292). The production of the immune regulatory markers IL-10, TGF- in 3LL and NCI-H292 cells increased after treatment with simvastatin. The expression of IDO and forkhead box P3 (FoxP3) transcription factor was also increased in the presence of simvastatin. In a murine 3LL model, there were no significant differences in tumour growth rate between untreated and simvastatin-treated mice groups. Therefore, while simvastatin had an anti-proliferative effect, it also exhibited immune tolerance-promoting properties during tumour development. Thus, due to these opposing actions, simvastatin had no net effect on tumour growth.

AB - Statins are potent inhibitors of hydroxyl-3-methylglutaryl co-enzyme A (HMG-CoA) reductase, and have emerged as potential anti-cancer agents based on preclinical evidence. In particular, compelling evidence suggests that statins have a wide range of immunomodulatory properties. However, little is known about the role of statins in tumour immune tolerance. Tumour immune tolerance involves the production of immunosuppressive molecules, such as interleukin (IL)-10, transforming growth factor (TGF)- and indoleamine-2,3-dioxygenase (IDO) by tumours, which induce a regulatory T cell (Treg) response. In this study, we investigated the effect of simvastatin on the production of IL-10, TGF- and IDO production and the proliferation of Tregs using several cancer cell lines, and Lewis lung cancer (3LL) cells-inoculated mouse tumour model. Simvastatin treatment resulted in a decrease in the number of cancer cells (3LL, A549 and NCI-H292). The production of the immune regulatory markers IL-10, TGF- in 3LL and NCI-H292 cells increased after treatment with simvastatin. The expression of IDO and forkhead box P3 (FoxP3) transcription factor was also increased in the presence of simvastatin. In a murine 3LL model, there were no significant differences in tumour growth rate between untreated and simvastatin-treated mice groups. Therefore, while simvastatin had an anti-proliferative effect, it also exhibited immune tolerance-promoting properties during tumour development. Thus, due to these opposing actions, simvastatin had no net effect on tumour growth.

KW - indoleamine-2,3-dioxygenase

KW - interleukin-10

KW - regulatory T cell

KW - statin

KW - transforming growth factor-β

UR - http://www.scopus.com/inward/record.url?scp=77954639908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954639908&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2249.2010.04170.x

DO - 10.1111/j.1365-2249.2010.04170.x

M3 - Article

C2 - 20491794

AN - SCOPUS:77954639908

VL - 161

SP - 298

EP - 305

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 2

ER -